Globestar Therapeutics Corporation  (GSTC)
Other Ticker:  
Price: $0.0008 $0.00 0.000%
Day's High: $0.0009 Week Perf: 14.29 %
Day's Low: $ 0.00 30 Day Perf: -63.64 %
Volume (M): 277 52 Wk High: $ 0.01
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1,004
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Globestar Therapeutics Corporation
Globestar Therapeutics Corporation is a biotechnology company that is focused on developing innovative therapies for neurological diseases and disorders. They are dedicated to advancing research and development in the field of neuroscience with the goal of improving the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

The company utilizes cutting-edge technologies and scientific insights to identify and develop potential drug candidates that target the underlying causes of these neurological disorders. Their approach involves a combination of drug discovery, preclinical testing, and clinical trials to ensure that their therapies are safe and effective.

Globestar Therapeutics Corporation also collaborates with academic institutions, research organizations, and other industry partners to leverage their expertise and resources. This collaborative approach allows them to tap into a diverse range of scientific knowledge and accelerate the development of their therapies.

Overall, Globestar Therapeutics Corporation is committed to bringing innovative neurological therapies to market and making a positive impact on patients' lives. They aim to address the unmet medical needs in the field of neuroscience and contribute to the advancement of treatments for neurological diseases.

   Company Address: 719 Jadwin Avenue Richland 99352 WA
   Company Phone Number: 451-1970   Stock Exchange / Ticker: GSTC


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Globestar Therapeutics Corporation

Globestar Therapeutics Corporation Reports Zero Gain and Stagnant Revenue in Q4 2023

Globestar Therapeutics Corporation, a leading pharmaceutical company, has recently released its financial results for the reporting period from October to December 31, 2023. During this period, the company reported zero gain at $0.00 per share, which is the opposite of its $0.00 per share gain in the previous year's reporting period. This is in line with the company's performance in the prior reporting period, where it also realized a gain of $0.00 per share.
In terms of revenue, Globestar Therapeutics Corporation reported zero million dollars for the October to December 31 time-frame, which remained unchanged from the preceding reporting period. This suggests that the company's revenue has remained stagnant, highlighting the need for new strategies to drive growth.

Globestar Therapeutics Corporation

Globestar Therapeutics Corporation Shows Encouraging Financial Growth in Q4 2023, Despite Operating Deficit2.

Interpreting the Financial Results of Globestar Therapeutics Corporation
As a seasoned financial analyst for the prestigious , it is my duty to interpret the latest financial results of companies for our esteemed readers. Today, the spotlight falls on the Major Pharmaceutical Preparations industry and its players, with specific attention on Globestar Therapeutics Corporation (GSTC).
In the fourth quarter of 2023, GSTC reported an operating deficit of $-0.287787 million. While this figure may sound alarming at first, it should be viewed as a positive surprise considering the lack of any top-line mentioned by GSTC. Without better benchmarks, the enhancement from the operating deficit in Q4 2022 of $-0.299843 million reinforces optimism among market participants.

Globestar Therapeutics Corporation

Globestar Therapeutics Corporation Reports Alarming Operating Deficit in Q3 2023 Earnings Season

The stock market has been abuzz with anticipation as we approach the April to June 30, 2023 reporting season. Stockholders have been eagerly awaiting updates on the business, hoping for positive adjustments and promising figures. However, recent developments have raised concerns, particularly regarding the operating deficit of GSTCsn.
During the aforementioned period, GSTCsn operating deficit reached a staggering $-1.279283 million. This is a significant deterioration compared to the third quarter of 2022, where the deficit stood at $-0.136618 million. The decline in the financial situation is undoubtedly worrying, and investors have been closely monitoring this alarming trend.

Globestar Therapeutics Corporation

Surprising Market Twist: Globestar Therapeutics Corp. Defies Forecasts by Displaying Significant Gain Despite Operating Shortfall in Q1 2023

The financial results for the Globestar Therapeutics Corporation (GSTC) for the January to March 31, 2023 reporting cycle have been released, and shareholders were not expecting any moderations at the top-line. However, it appears that they are paying a significant amount of attention to the company's operating shortfall, which was reported at $-0.142059 million during the same period. One positive aspect of this result is that it compares favorably to the performance of the second quarter of 2022, where the operating shortfall was significantly higher at $-0.66231 million. This appears to be a significant indicator for the company's course going forward.
For a company like GSTC, which is on an upward trajectory in terms of revenue generation, it becomes increasingly important to run cost-effectively in order to reach the next chapter of its growth. The good news is that there has been some alleviation on the bottom-line, as the diminishing returns have been cut from the same time frame a year prior. The fiscal span ending in the second quarter of 2023 saw a loss of $-0.150 million, which is lower than the loss of $-0.689 million reported in the same period in 2022. This is a major takeaway from the most recent financial results, which indicates that GSTC is moving in the right direction, albeit at a steady pace.


Globestar Therapeutics's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com